NCT07476807Enrolling by invitation
Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study
TREATS: Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study
Source: ClinicalTrials.gov · Last updated 28 Apr 2026
Brief summary (registry, in English)
This study is being done to find out if video consultations (telemedicine) can be used to safely and effectively assess and manage skin problems caused by cancer treatments. Instead of always coming to the hospital for a face-to-face appointment, the patient may be able to use thier smartphone or computer to show your skin to a nurse or doctor over a secure video call. the researchers want to see if this is as good as a regular clinic visit, and whether patients and staff are happy with this new way of working.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 27 Feb 2026
- Start date
- Apr 2026
- Primary completion date
- Apr 2026
- Lead sponsor
- Sligo General Hospital
- Diseases
- Childhood cancers
- NCT number
- NCT07476807
What you commit to
- Study type: Interventional
- Planned participants: 25
- From Apr 2026 to the primary completion date, Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Skin toxicity graded ≥ Grade 3 according to UKONS assessment criteria.
- Clinical status requiring urgent or immediate face-to-face medical assessment.
- Dermatologic toxicity that is atypical, unexpected, or not consistent with known SACT-related adverse effects.
- Inability to access or effectively use the required telemedicine technology.
Who the study is looking for
- Adult oncology or haematology patients currently receiving systemic anti-cancer therapy (SACT).
- New-onset dermatologic toxicity consistent with a recognised adverse effect of the administered SACT.
- Skin toxicity severity graded ≤ Grade 2 in accordance with UKONS assessment criteria.
- Clinically stable condition not requiring urgent in-person evaluation.
- Access to, and ability to use, a smartphone or computer with adequate internet connectivity to participate in telemedicine consultations.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sligo University Hospital Coordinator of this site? Confirm its status | Sligo | Ireland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.